Overview
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
Eligibility
Inclusion Criteria:
- Male or female aged 18-60.
- Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2.
- Chronic HBV infection for ≥ 6 months.
- On NRTI therapy for at least 6 months.
Exclusion Criteria:
- Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation.
- Significant liver fibrosis or cirrhosis.
- History or evidence of drug or alcohol abuse.
- History of intolerance to SC injection.
- History of chronic liver disease from any cause other than chronic HBV infection.
- History of hepatic decompensation.
- Contraindications to the use of Peg-IFNα.
